Scottish cleantech innovators Celtic Renewables launched its Crowdcube funding campaign on the back of investor appetite to fund companies with environmental, social and governance (ESG) factors. With commissioning of Celtic Renewables’ biorefinery in Scotland – the first of its kind in the UK – on track for Spring 2021, and on the back of £30 million funding already raised; the business is poised to play a pivotal role in the UK’s transition to net-zero economy.
Celtic Renewables Ltd, the innovative Scottish start-up providing next generation biofuel, is building a commercial demonstrator plant, which will produce over half a million litres of biofuel each year.
“The UK cannot solve the problem on its own, and we will need to collaborate with foreign governments and companies if we are to truly tackle the crisis ahead.” To say it referring to Brexit – in this exclusive interview with Il Bioeconomista – is Jaymin Amin, COO at Ingenza, the spin-out from the University of Edinburgh founded in 2002, which is today one of the most dynamic European industrial biotech company. With Amin we talk about industrial biotechnology and bioeconomy in Scotland.
Interview by Mario Bonaccorso
“Scotland has under 10% of the UK population and over 30% of the land mass giving it considerably more capacity for growing biomass as feedstock for the bioeconomy. Scotland has great research capabilities, a strong base of SMEs looking to develop its bio-capabilities and the joined up support of the government with all its agencies in developing this opportunity”. Roger Kilburn, CEO IBioIC (Industrial Biotechnology Innovation Centre) Scotland, talks to Il Bioeconomista. In this long, exclusive interview, he talks about UK and Scottish bioeconomy, the role of industrial biotechnology and Brexit. “The fundamental reasons for developing the bioeconomy – he says – are the positive impact it has on sustainability, the environment and the ability to produce new and improved materials. None of these fundamentals are affected by Brexit”.
Interview by Mario Bonaccorso
Scotland is set to create waves among the global biotechnology arena as its Industrial Biotechnology Innovation Centre (IBioIC) announces over £3 million of investment across six game changing synthetic biology projects including greener skincare products, more sustainable plastics and improvements to personalised medicine therapies.
Everything is ready in Glasgow, Scotland, to host the European Forum for Industrial Biotechnology and Bioeconomy. Taking place on 18-20 October at the Scottish Exhibition and Conference Centre, EFIB 2016 – organised by EuropaBio and Smithers Rapra – will take advantage of the opportunity to increase engagement between policy makers and a broad range of stakeholders connected with the existing biobased value chain, and reach a new network of end users from a range of industries.
“Investments should be made in the bioeconomy because it is the future. Although it is still in the early years of development, there is little doubt that this area will become important.” To say it, in this exclusive interview with Il Bioeconomista, is Christian Kemp Griffin, executive director and Ceo of CelluComp, a dynamic material science company based in Scotland that develops high performance products based on sustainable resources. With Kemp-Griffin we talk about CelluComp and the development of the bioeconomy.
Interview by Mario Bonaccorso
A new innovation centre for industrial biotechnology is forecast to increase industrial biotechnology-related turnover to up to £3 billion by 2030, create 1500 jobs within five years and put Scotland at the forefront of a global transformation. Funded by the Scottish Funding Council and supported by Scottish Enterprise and Highlands & Islands Enterprise, the new Industrial Biotechnology Innovation Centre (IBioIC) – hosted at the University of Strathclyde – is a key element of the National Plan for Industrial Biotechnology – Towards a Greener, Cleaner 2025. It brings together academic and private sector partners to play a leading role in the potential £360 billion global industrial biotechnology market. Industrial biotechnology is the use of biological substances, systems and processes to produce intermediate and final products such as pharmaceuticals, chemicals, materials and energy – both cost-effectively and with minimal adverse environmental impact.
IL BIOECONOMISTA 